Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma

Lu‐Lu Zhang, Xi Chen, Yingying Huang, Chixiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jiayu Zhou, Hao‐Yang Huang, Xiang Guo, Xing LvCancer 2023 · DOI

TL;DR

This study investigated serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC) patients, finding it occurs in 5.21% of cases and is linked to a worse long-term prognosis. The research identified several key predictors of CIT, including specific chemotherapy regimens and various blood/kidney function markers, offering potential avenues for early intervention and risk stratification.

What Problem Does This Paper Address?

Nasopharyngeal carcinoma (NPC) is a significant cancer, and while radiotherapy and chemotherapy are primary treatment modalities, chemotherapy can lead to serious side effects. One such severe complication is chemotherapy-induced thrombocytopenia (CIT), a condition where platelet counts drop dangerously low. This can necessitate dose reductions, delays, or even discontinuation of chemotherapy, potentially impacting treatment efficacy and patient outcomes. While CIT is a known risk, its specific incidence, long-term consequences, and reliable predictors in the context of NPC treatment were not well-established. This paper aims to fill that knowledge gap by examining these aspects in a large cohort of NPC patients.

Methods

The researchers conducted a retrospective study, analyzing the clinical records of newly diagnosed, non-metastatic NPC patients treated between 2013 and 2015. They employed several statistical techniques:

  • Propensity Score Matching (PSM): To create comparable groups of patients with and without serious CIT, balancing potential confounding factors and allowing for a more robust comparison of outcomes.
  • Multivariate Cox Proportional Hazards Regression: Used to estimate the effect of serious CIT on overall survival (OS), accounting for various covariates.
  • Univariate and Multivariate Logistic Regression: Applied to identify predictors of serious CIT.
  • Receiver Operating Characteristic (ROC) Curve Analysis: Used to determine optimal thresholds for certain predictive markers.

Serious CIT was defined as grade 3-4 thrombocytopenia occurring within 120 days of treatment initiation, based on CTCAE v5.0 criteria.

Datasets

The study utilized a dataset of 3933 newly diagnosed, non-metastatic nasopharyngeal carcinoma patients from the Sun Yat-Sen University Cancer Center (SYSUCC) between 2013 and 2015. This retrospective cohort served as the primary data source for analysis.

Key Insights and Ideas

  • CIT's Long-Term Impact: While short-term survival differences between patients with and without serious CIT were minimal, the study clearly demonstrates a significantly worse long-term prognosis for those experiencing severe thrombocytopenia. This highlights the importance of managing CIT not just for immediate safety but for sustained patient outcomes.
  • Predictive Power of Blood Markers: The identification of serum potassium (K+), lactate dehydrogenase (LDH), red blood cell (RBC) count, and platelet (PLT) count as predictors is crucial. This suggests that routine blood work can offer early warnings for patients at higher risk of developing serious CIT.
  • Kidney Function as a Factor: Estimated glomerular filtration rate (eGFR) emerged as a protective factor against CIT. This implies that better kidney function might help patients tolerate chemotherapy better, potentially by facilitating drug excretion.
  • Chemotherapy Regimen Specificity: Certain chemotherapy combinations, particularly gemcitabine and platinum (GP), 5-fluorouracil and platinum (PF), and taxane and platinum (TP), were identified as significant predictors of serious CIT. This information can guide oncologists in selecting less toxic regimens or implementing closer monitoring for patients on these specific treatments.

Key Results

  • Incidence: Serious CIT occurred in 5.21% (205 out of 3933) of NPC patients within 120 days of treatment.
  • Survival: After propensity score matching, patients with serious CIT had a significantly lower 5-year overall survival rate (82.5%) compared to those without serious CIT (90.9%).
  • Predictors of Serious CIT: The final multivariate logistic regression identified the following as significant predictors:
  • Chemotherapy regimens: GP (OR=6.30), PF (OR=4.51), TP (OR=2.05)
    • Biomarkers: Higher serum K+ (OR=1.57), higher LDH (≥245 U/L) (OR=1.83), lower RBC count (OR=0.62), lower eGFR (OR=0.98), lower PLT count (OR=0.99).
  • Treatment Modifications: Patients who had chemotherapy dose reduction or stopped treatment due to CIT showed a trend towards poorer OS, though this was not statistically significant after adjustment. Similarly, delays in chemotherapy did not significantly impact OS.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-Center Study: The data was collected from a single institution, which may limit the generalizability of the findings to other populations or healthcare settings.
  • Retrospective Design: As with all retrospective studies, there's an inherent risk of bias and limitations in data completeness.
  • Subgroup Analysis Sample Size: The sample sizes for subgroup analyses (e.g., regarding treatment modifications) were small, potentially limiting the power to detect significant differences.
  • Mechanism Unclear: While predictors are identified, the underlying molecular mechanisms for many associations (e.g., LDH and K+ with CIT) require further investigation.

Future work suggested includes:

  • Exploring the mechanisms behind the identified predictors.
  • Investigating the role of thrombopoietic agents in managing CIT and their impact on long-term survival.
  • Examining how the tumor microenvironment changes with CIT.
  • Validating these findings in larger, multi-center prospective studies.
  • Determining if these predictors apply to patients with pre-existing low WBC or platelet counts.

Summary updated

Abstract

The incidence of serious CIT was 5.21% in patients with NPC. Patients who experienced serious thrombocytopenia had a worse long-term prognosis, while the difference in short-term survival rate was slight. Chemotherapy regimens of gemcitabine and platinum, 5-fluorouracil and platinum, taxane and platinum, serum potassium ion concentration, serum lactate dehydrogenase levels, platelet count, red blood cell count, and estimated glomerular filtration rate were predictors of serious CIT.
BibTeX
@inproceedings{zhang2023incidence,
  author = {Lu‐Lu Zhang and Xi Chen and Yingying Huang and Chixiong Liang and Meng‐Yun Qiang and Zhuo‐Chen Cai and Ze‐Jiang Zhan and Ying Deng and Jiayu Zhou and Hao‐Yang Huang and Xiang Guo and Xing Lv},
  title = {{Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1002/cam4.6062},
}
Figure